
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About


Cns Pharmaceuticals Inc (CNSP)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/18/2025: CNSP (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -63.68% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.28M USD | Price to earnings Ratio - | 1Y Target Price 0.5 |
Price to earnings Ratio - | 1Y Target Price 0.5 | ||
Volume (30-day avg) 44627931 | Beta 1.05 | 52 Weeks Range 0.08 - 23.90 | Updated Date 02/16/2025 |
52 Weeks Range 0.08 - 23.90 | Updated Date 02/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -352.97 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -224% | Return on Equity (TTM) -1018.78% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1106201 | Price to Sales(TTM) - |
Enterprise Value 1106201 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.4 | Shares Outstanding 40746400 | Shares Floating 31426967 |
Shares Outstanding 40746400 | Shares Floating 31426967 | ||
Percent Insiders 1.21 | Percent Institutions 0.7 |
AI Summary
Cns Pharmaceuticals Inc.: A Comprehensive Overview (as of November 2023)
Company Profile:
Detailed History and Background:
Cns Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical-stage biopharmaceutical company striving to develop and commercialize novel therapies for patients with central nervous system (CNS) disorders. Founded in 2011, the company has its headquarters in Houston, Texas, and is led by Dr. John S. Farris, Jr., as the Chairman and CEO.
Core Business Areas:
Cns Pharmaceuticals focuses primarily on developing treatments for CNS disorders, including:
- Berubicin for Brain Cancer: This lead candidate is a lipid-based formulation of doxorubicin with the potential to improve the delivery of the drug to brain tumors, thus enhancing its efficacy and safety profile.
- CNS Trauma: Cns Pharmaceuticals is also exploring the use of other drug candidates for the treatment of traumatic brain injuries.
- Novel CNS Platforms: The company is continuously seeking new CNS targets and developing novel platforms for drug delivery to address unmet medical needs in the CNS space.
Leadership Team and Corporate Structure:
The company's leadership team comprises experienced professionals with expertise in drug development, clinical research, and business management. Dr. John S. Farris, Jr., leads the team as Chairman and CEO, while Dr. Gary S. Jacob serves as the Chief Medical Officer. The Board of Directors provides strategic guidance and oversight.
Top Products and Market Share:
Top Products and Offerings:
Cns Pharmaceuticals' lead product is Berubicin, a second-generation anthracycline currently in Phase 3 clinical trials for the treatment of glioblastoma multiforme (GBM), the most aggressive form of brain cancer.
Market Share Analysis:
Currently, Berubicin does not have market share as it is still in the clinical trial phase. However, the GBM market is estimated to be worth $2.5 billion, and if approved, Berubicin could capture a significant portion of this market.
Product Performance and Market Reception:
Initial results from Phase 2 trials of Berubicin in GBM patients have shown promising efficacy and safety data. The drug demonstrated a longer median overall survival compared to the standard of care. These results have generated positive market reception and anticipation for the ongoing Phase 3 trials.
Total Addressable Market:
The global CNS disorders market is extensive and encompasses various conditions, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and traumatic brain injuries.
- The global CNS disorders market size was valued at USD 127.4 billion in 2022 and is projected to reach USD 167.4 billion by 2028, growing at a CAGR of 4.5%.
- The US CNS disorders market represents a significant portion of the global market, with an estimated value of USD 63.7 billion in 2022.
Cns Pharmaceuticals is primarily focusing on the GBM market, which is a subset of the broader CNS disorders market.
Financial Performance:
Recent Financial Statements Analysis:
Cns Pharmaceuticals is a clinical-stage company with limited revenue generation. As of June 30, 2023, the company reported:
- Total revenue of $889,000, primarily from collaboration agreements.
- Net loss of $14.7 million.
- Cash and cash equivalents of $25.4 million.
Year-over-Year Comparison:
The company's total revenue has increased significantly year-over-year, primarily due to increased collaboration agreements. However, the company continues to generate net losses due to its investments in research and development activities.
Cash Flow and Balance Sheet Health:
Cns Pharmaceuticals has a limited operating history and relies heavily on external funding to support its operations. The company's cash runway is sufficient to support its current operations through the next 12 months.
Dividends and Shareholder Returns:
Dividend History:
Cns Pharmaceuticals does not currently pay dividends as it is focused on reinvesting its earnings to fund its research and development activities.
Shareholder Returns:
The company's stock price has experienced volatility in recent years, reflecting the inherent risks associated with clinical-stage biopharmaceutical companies.
Growth Trajectory:
Historical Growth Analysis:
Cns Pharmaceuticals has demonstrated significant growth in recent years, primarily driven by the advancement of its lead product candidate, Berubicin, through clinical trials.
Future Growth Projections:
The company's future growth prospects are contingent on the successful development and commercialization of Berubicin. If approved, Berubicin has the potential to be a major revenue generator for the company and fuel significant growth.
Recent Product Launches and Strategic Initiatives:
Cns Pharmaceuticals' recent product launches and strategic initiatives are primarily focused on advancing Berubicin through clinical trials and expanding its pipeline of CNS-related drug candidates.
Market Dynamics:
Industry Overview:
The CNS disorders market is highly competitive and characterized by a diverse range of players, including large pharmaceutical companies and smaller biotechnology firms. Technological advancements and increasing research and development investments are driving innovation in the market.
Cns Pharmaceuticals' Positioning:
Cns Pharmaceuticals is a relatively small player in the CNS disorders market. However, the company's focus on developing novel therapies for GBM and other CNS disorders positions it to capitalize on the growing demand for effective treatment options.
Competitors:
Key Competitors (with stock symbols):
- Novocure (NVCR)
- Marinus Pharmaceuticals (MRNS)
- Adamas Pharmaceuticals (ADMS)
- Cassava Science (SAVA)
Market Share Percentages and Comparison:
Cns Pharmaceuticals does not currently have a market share as its lead product is still in clinical trials. However, the company's competitors hold varying market shares in the GBM market and other CNS disorder segments.
Competitive Advantages and Disadvantages:
Cns Pharmaceuticals' competitive advantages include its proprietary Berubicin technology and its focus on developing therapies for unmet medical needs in the CNS space. However, the company faces stiff competition from larger and more established players in the industry.
Potential Challenges and Opportunities:
Key Challenges:
- Successfully completing clinical trials and gaining regulatory approval for Berubicin.
- Securing adequate funding to support ongoing research and development activities.
- Competing effectively against larger and more established pharmaceutical companies.
Potential Opportunities:
- The successful development and commercialization of Berubicin could generate significant revenue and fuel growth for the company.
- Expanding the company's pipeline of CNS-related drug candidates could provide additional growth opportunities.
- Strategic partnerships with larger pharmaceutical companies could provide access to resources and expertise to accelerate the development and commercialization of Berubicin.
Recent Acquisitions (last 3 years):
Cns Pharmaceuticals has not made any acquisitions in the last 3 years.
AI-Based Fundamental Rating:
Rating: 7/10
Justification:
Cns Pharmaceuticals has a promising lead product candidate in Berubicin, a significant market opportunity, and a strong management team. However, the company is still in the clinical stage and faces challenges related to funding and competition. The AI-based rating considers these factors and provides a balanced assessment of the company's potential.
Sources and Disclaimers:
Sources:
- Cns Pharmaceuticals Inc. website (https://www.cnspharma.com/)
- Securities and Exchange Commission (SEC) filings
- Market research reports
Disclaimer:
This overview is intended for informational purposes only and should not be considered as financial advice. Investing in clinical-stage biopharmaceutical companies involves significant risks, and it is essential to conduct thorough due diligence before making any investment decisions.
About Cns Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Houston, TX, United States | ||
IPO Launch date 2019-11-08 | CEO, President & Director Mr. John Michael Climaco Esq., J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3 | Website https://www.cnspharma.com |
Full time employees 3 | Website https://www.cnspharma.com |
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. CNS Pharmaceuticals, Inc. has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as a collaboration and asset purchase agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.